Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...

Novo Nordisk (NVO) ended the recent trading session at $67.10, demonstrating a -1.67% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of ...

KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG , Bloomberg News reported on Thursday, ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

At the helm of Denmark’s economic success is Novo Nordisk, the pharma company that makes Ozempic and Wegovy, blockbuster ...

Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

President Trump has announced sweeping tariffs on several countries. Novo Nordisk and Smith & Nephew may be the most at risk ...

Novo Nordisk has announced major leadership changes, with EVP Camilla Sylvest departing and Ludovic Helfgott taking on an ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK822.00.